Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Advanced 37.3% over 21 sessions to a period high. Q2 2026 XDEMVY sales grew more than 69% year over year to $173.9 million, while the planned Alkeus acquisition, positive TEASE-1 results, and a $125 million PIPE provide commercial, pipeline, and liquidity catalysts.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Persistent Losses ⢠Rising Dilution TARS has ample liquidity and improving quarterly cash flow, but persistent losses, rising leverage and dilution, and premium valuation multiples warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Strong Monthly Gain ⢠Resistance Consolidation ⢠Support Watch Support Level: $70.60â$71.00 Resistance Level: $72.80â$73.45 TARS remains bullish over the last month but is consolidating below $73.45 resistance; watch $70.60 support for trend confirmation or breakdown.
Sentiment & News
Key News Insights: ⢠XDEMVY sales surge ⢠Alkeus expands pipeline ⢠Funding supports growth Tarsus's surging XDEMVY sales, $125M financing, and Alkeus acquisition strengthen growth prospects despite a wider-than-expected quarterly loss.
AI Summary
TARS is evolving from a high-growth XDEMVY commercial story into a higher-risk ophthalmology platform bet, where sustained XDEMVY growth and SG&A discipline must fund the Alkeus acquisition and validate operating leverage; investors should favor the shares only if revenue momentum persists without further meaningful dilution, treating gildeuretinol as option value rather than core valuation support.
Description
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for ophthalmic and related conditions. Its lead candidate, TP-03, is in Phase III for blepharitis associated with Demodex infestation and for meibomian gland disease, while additional pipeline programs include treatments for rosacea, Lyme prophylaxis, and malaria reduction. The company also develops the lotilaner molecule for use across eye care, dermatology and other human medicine indications and is headquartered in Irvine, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 3 | Sep 10 | TARS | Tarsus Pharmaceuticals, Inc. | Advanced 37.3% over 21 sessions to a period high. Q2 2026 XDEMVY sales grew more than 69% year over year to $173.9 million, while the planned Alkeus acquisition, positive TEASE-1 results, and a $125 million PIPE provide commercial, pipeline, and liquidity catalysts. | Active | +0.0% |